JPRN-UMIN000013586
Recruiting
Phase 2
Randomised phase 2 trial of gefitinib plus bevacizumab vs gefitinib alone in patients with EGFR mutant non-squamous non small cell lung cance - BAGEL study
BAGEL study group0 sites90 target enrollmentMay 12, 2014
Conditionsnon small cell lung cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- non small cell lung cancer
- Sponsor
- BAGEL study group
- Enrollment
- 90
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) History of drug induced interstitial pneumonia or radiation pneumonitis that need steroid therapy. Interstitial pneumonitis or pulmonary fibrosis as determined from chest CT 2\) EGFR mutation that associates with gefitinib resistance (exon 20 T790M) 3\) central nervous system metastases 4\) spinal cord compression 5\) Active concomitant malignancy 6\) Currently have or have a history of hemoptysis 7\) bleeding tendency (coagulation disorder) 8\) Patients receiving therapeutic anticoagulation 9\) Uncontrolled effusion (Pleural, peritoneal effusion, or cardiac effusion which requires drainage for symptom management) 10\) History of gastrointestinal perforation 11\) History of serious systemic disease including: clinically significant cardiovascular disease; medically uncontrolled diabetes and hypertension; active gastrointestinal ulcer, acive psychological disorders 12\) Clinically significant drug allergy 13\) Serious concomitant active infection 14\) Receiving systemic corticosteroid therapy within 2 weeks of registration 15\) Major surgery within 3 weeks of registration, radiotherapy within 2 weeks of registration 16\) Pregnant or breast\-feeding woman 17\) Not suitable for participating in the study for any other reason
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A phase II trial of gefitinib in combination with bevacizumab as first line therapy for advanced non-small-cell lung cancer with mutated EGFRnon-small-cell lung cancerJPRN-UMIN000004296Okayama Lung Cancer Study Group42
Completed
Phase 2
Randomized phase II study of continuous gefitinib plus chemotherapy versus alternation of gefitinib and chemotherapy in previously untreated non-small cell lung cancer (NSCLC) with sensitive EGFR mutations (NEJ005/TCOG0902)on-small cell lung cancer with EGFR mutations (non-squamous histology)JPRN-UMIN000002789orth East Japan Study Group/The Tokyo Cooperative Oncology Group80
Not yet recruiting
Phase 3
A study to compare Gefitinib & bevacizumab with gefitinib alone in lung cancer patientsHealth Condition 1: null- Lung Cancer PatientsCTRI/2018/04/013399Tata Memorial Hospital
Completed
Phase 2
Phase II trial of induction gefitinib followed by cisplatin and docetaxel with concurrent radiotherapy in locally advanced non-small cell lung cancer with EGFR activating mutationon-small cell lung cancerJPRN-UMIN000005086ung Oncology Group in Kyushu, Japan (LOGIK)21
Completed
Phase 2
A phase II trial of gefitinib and concurrent radiation therapy for locally advanced non-small cell lung cancer patients harboring sensitive EGFR mutations.on-small cell lung cancerJPRN-UMIN000003274ational Hospital Organization15